OSTEOAMP SELECT Fibers Launched by Bioventus

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

AAOS on IPO Elimination Reversal in 2022 CMS Outpatient Rule

AAOS is encouraged to hear that CMS has heeded the patient safety concerns of the physician community regarding the abrupt elimination of the Inpatient Only.

Stryker Steps up to the Plate at Chickasaw Bricktown Ballpark with Its SmartRobotics™ Technology

Stryker, the Official SmartRobotics™ Joint Replacement Partner of Minor League Baseball, showcases its Mako SmartRobotics™ Technology to Oklahoma City Dodgers fans.

Bioventus, (orthobiologic solutions) has launched OSTEOAMP SELECT Fibers, an innovative addition to its allograft line of OSTEOAMP bone graft substitutes for spine, foot & ankle, orthopaedic, and trauma surgeons. OSTEOAMP SELECT Fibers are uniquely processed to retain essential growth factors supporting bone formation1* and the nanotextured fibers provide a conduit for cell migration.

OSTEOAMP SELECT Fibers
OSTEOAMP SELECT Fibers

OSTEOAMP SELECT Fibers also advance the handling properties of allograft bone graft substitutes by providing versatile handling for users. The interlocking fibers have high fluid retention and the ability to expand, while maintaining integrity and position.2 These handling properties allow it to be easily molded and packed into place to conform to irregular bone voids.

“OSTEOAMP SELECT Fibers have already been successfully utilized in multiple procedure types in both spine and foot and ankle specialties. Its absorption profile and ability to expand provide surgeons with clinical flexibility as the interlocking fibers can be easily molded and packed to conform to any bone void,” said Tony Bihl, CEO, Bioventus. “This new allograft solution joins our original OSTEOAMP offerings in putty, sponge and granule formats, giving surgeons more options for bone healing and remodeling while delivering positive patient outcomes.”

Bioventus reports OSTEOAMP SELECT Fibers comes in five sizes from 1 to 15 cc and is available now from distributors nationwide.


References

References:
1. Tidwell JL., Seaman SA, Vanderploeg EJ, Tom S. In vitro and in vivo characterization of OSTEOAMP allogenic morphogentic proteins. Data on file. Bioventus white paper, 2017.
2. Data on file RPT-000858. OSTEOAMP Absorption Data.
*In vitro performance may not be predictive of performance in humans.

spot_img

DON'T MISS

Dr. Woodrow Myers Joins the Freespira Board of Directors

Former Blue Cross Blue Shield Health Plan chief medical officer and chief healthcare strategist brings clinical, quality and business insights to fast-growing digital therapeutic company.

Avanos Medical, Inc. Appoints Moji James as Senior Vice President & General Counsel

Prior to Tmunity, James served as senior vice president and general counsel of Iroko Pharmaceuticals, and she began her life sciences legal career at Wyeth Pharmaceuticals (now part of Pfizer).

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.